nach oben

Erschienen in:

27.01.2021 | Review

Viral infections and their relationship to neurological disorders

verfasst von: Jéssica Wouk, Daniele Zendrini Rechenchoski, Bianca Cerqueira Dias Rodrigues, Elisa Vicente Ribelato, Ligia Carla Faccin-Galhardi

Erschienen in: Archives of Virology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

The chronic dysfunction of neuronal cells, both central and peripheral, a characteristic of neurological disorders, may be caused by irreversible damage and cell death. In 2016, more than 276 million cases of neurological disorders were reported worldwide. Moreover, neurological disorders are the second leading cause of death. Generally, the etiology of neurological diseases is not fully understood. Recent studies have related the onset of neurological disorders to viral infections, which may cause neurological symptoms or lead to immune responses that trigger these pathological signs. Currently, this relationship is mostly based on epidemiological data on infections and seroprevalence of patients who present with neurological disorders. The number of studies aiming to elucidate the mechanism of action by which viral infections may directly or indirectly contribute to the development of neurological disorders has been increasing over the years but these studies are still scarce. Comprehending the pathogenesis of these diseases and exploring novel theories may favor the development of new strategies for diagnosis and therapy in the future. Therefore, the objective of the present study was to review the main pieces of evidence for the relationship between viral infection and neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Guillain-Barré syndrome, multiple sclerosis, and epilepsy. Viruses belonging to the families Herpesviridae, Orthomyxoviridae, Flaviviridae, and Retroviridae have been reported to be involved in one or more of these conditions. Also, neurological symptoms and the future impact of infection with SARS-CoV-2, a member of the family Coronaviridae that is responsible for the COVID-19 pandemic that started in late 2019, are reported and discussed.

Lovrečić L, Maver A, Zadel M, Peterlin B (2013) The role of epigenetics in neurodegenerative diseases. In: Kishore U (ed) Neurodegenerative diseases. IntechOpen, pp 345–365. https://doi.org/10.5772/54744. https://www.intechopen.com/books/neurodegenerative-diseases/the-role-of-epigenetics-in-neurodegenerative-diseases. Accessed 21 Jan 2021

GBD 2016 Multiple Sclerosis Collaborators (2019) Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(3):269–285. https://doi.org/10.1016/S1474-4422(18)30443-5CrossRef

Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29(8):357–365. https://doi.org/10.1016/j.it.2008.05.002CrossRef

Brown RC, Lockwood AH, Sonawane BR (2005) Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 113(9):1250–1256. https://doi.org/10.1289/ehp.7567CrossRef

Karatas H, Gurer G, Pinar A et al (2008) Investigation of HSV-1, HSV-2, CMV, HHV-6 and HHV-8 DNA by real-time PCR in surgical resection materials of epilepsy patients with mesial temporal lobe sclerosis. J Neurol Sci 264(1–2):151–156. https://doi.org/10.1016/j.jns.2007.08.010CrossRef

Jacobs BC, Rothbarth PH, van der Meché FG et al (1998) The spectrum of antecedent infections in Guillain–Barré syndrome: a case-control study. Neurology 51(4):1110–1115. https://doi.org/10.1212/wnl.51.4.1110CrossRef

Itzhaki RF (2016) Herpes and Alzheimer’s disease: subversion in the central nervous system and how it might be halted. J Alzheimers Dis. 54(4):1273–1281. https://doi.org/10.3233/JAD-160607CrossRef

Jang H, Boltz D, Mcclaren J et al (2012) Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice. J Neurosci 32(5):1545–1559. https://doi.org/10.1523/jneurosci.5123-11.2012CrossRef

Eldridge R, Osorio D, Amstalden K et al (2020) Antecedent presentation of neurological phenotypes in the Collaborative Cross reveals four classes with complex sex-dependencies. Sci Rep 10:7918. https://doi.org/10.1038/s41598-020-64862-zCrossRef

10.

Zhou L, Miranda-Saksena M, Saksena NK (2013) Viruses and neurodegeneration. Virol J 10:172. https://doi.org/10.1186/1743-422X-10-172CrossRef

11.

Berk C, Paul G, Sabbagh M (2014) Investigational drugs in Alzheimer’s disease: current progress. Expert Opin Investig Drugs 23(6):837–846. https://doi.org/10.1517/13543784.2014.905542CrossRef

12.

Bowery NG, Bagetta G, Nisticó G et al (1992) Intrahippocampal tetanus toxin produces generalized convulsions and neurodegeneration in rats: antagonism by NMDA receptor blockers. Epilepsy Res Suppl 9:249–256 (PMID: 1363043)

13.

Cermelli C, Vinceti M, Beretti F et al (2003) Risk of sporadic amyotrophic lateral sclerosis associated with seropositivity for herpesviruses and echovirus-7. Eur J Epidemiol 18(2):123–127. https://doi.org/10.1023/a:1023067728557CrossRef

14.

Takahashi M, Yamada T (1999) Viral etiology for Parkinson’s disease–a possible role of influenza A virus infection. Jpn J Infect Dis 52(3):89–98 (PMID: 10507986)CrossRef

15.

Balin BJ, Gérard HC, Arking EJ et al (1998) Identification and localization of Chlamydia pneumoniae in the Alzheimer’s brain. Med Microbiol Immunol 187(1):23–42. https://doi.org/10.1007/s004300050071CrossRef

16.

De Chiara G, Marcocci ME, Sgarbanti R et al (2012) Infectious agents and neurodegeneration. Mol Neurobiol 46(3):614–638. https://doi.org/10.1007/s12035-012-8320-7CrossRef

17.

Wang J, Ben JG, Colin LM et al (2017) A systemic view of Alzheimer disease—insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol 13(10):612–623. https://doi.org/10.1038/nrneurol.2017.111CrossRef

18.

McGavern DB, Kang SS (2011) Illuminating viral infections in the nervous system. Nat Rev Immunol 1(5):318–329. https://doi.org/10.1038/nri2971CrossRef

19.

Mattson MP (2004) Infectious agents and age-related neurodegenerative disorders. Ageing Res Rev 3(1):105–120. https://doi.org/10.1016/j.arr.2003.08.005CrossRef

20.

Strazza M, Pirrone V, Wigdahl B et al (2011) Breaking down the barrier: the effects of HIV-1 on the blood–brain barrier. Brain Res 1399:96–115. https://doi.org/10.1016/j.brainres.2011.05.015CrossRef

21.

Hsieh MJ, White PJ, Pouton CW (2010) Interaction of viruses with host cell molecular motors. Curr Opin Biotechnol 21(5):633–639. https://doi.org/10.1016/j.copbio.2010.06.009CrossRef

22.

Matsuda K, Park CH, Sunden Y et al (2004) The vagus nerve is one route of transneural invasion for intranasally inoculated influenza a virus in mice. Vet Pathol 41(2):101–107. https://doi.org/10.1354/vp.41-2-101CrossRef

23.

Salinas S, Schiavo G, Kremer EJ (2010) A hitchhiker’s guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol 8(9):645–655. https://doi.org/10.1038/nrmicro2395CrossRef

24.

Lucatelli JF, Barros AC, Maluf SW et al (2009) Influência genética sobre a doença de Alzheimer de início precoce. Rev Psiq Clín 36(1):25–30. https://doi.org/10.1590/S0101-60832009000100004CrossRef

25.

Alonso Vilatela ME, López-López M, Yescas-Gómez P (2012) Genetics of Alzheimer’s disease. Arch Med Res 43(8):622–631. https://doi.org/10.1016/j.arcmed.2012.10.017CrossRef

26.

Rall SC Jr, Weisgraber KH, Mahley RW (1982) Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 257(8):4171–4178 (PMID: 7068630)CrossRef

27.

Masters CL, Selkoe DJ (2012) Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2(6):a006262. https://doi.org/10.1101/cshperspect.a006262CrossRef

28.

Cárdenas-Aguayo MDC, Silva-Lucero MDC, Cortes-Ortiz M et al (2014) Physiological role of amyloid β in neural cells: the cellular trophic activity. In: Heinbockel T (ed) Neurochemistry. Intechopen, London, pp 257–281

29.

De-Paula VJ, Radanovic M, Diniz BS et al (2012) Alzheimer’s disease. Subcell Biochem 65:329–352. https://doi.org/10.1007/978-94-007-5416-4_14CrossRef

30.

Kolarova M, García-Sierra F, Bartos A et al (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012:731526. https://doi.org/10.1155/2012/731526CrossRef

31.

Mondragón-Rodríguez S, Perry G, Zhu X et al (2013) Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer’s disease. Oxid Med Cell Longev 2013:940603. https://doi.org/10.1155/2013/940603CrossRef

32.

Wang JM, Sun C (2010) Calcium and neurogenesis in Alzheimer’s disease. Front Neurosci 4:194. https://doi.org/10.3389/fnins.2010.00194CrossRef

33.

Arispe N, Rojas E, Pollard HB (1993) Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 90(2):567–571. https://doi.org/10.1073/pnas.90.2.567CrossRef

34.

Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev 2013:316523. https://doi.org/10.1155/2013/316523 (Epub 2013 Jul 25)CrossRef

35.

Boland B, Kumar A, Lee S et al (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci 28(27):6926–6937. https://doi.org/10.1523/JNEUROSCI.0800-08.2008CrossRef

36.

Wang X, Wang W, Li L et al (1842) (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta 8:1240–1247. https://doi.org/10.1016/j.bbadis.2013.10.015CrossRef

37.

Reddy PH, Mani G, Park BS et al (2005) Differential loss of synaptic proteins in Alzheimer’s disease: implications for synaptic dysfunction. J Alzheimers Dis. 7(2):103–17; discussion 173–80. https://doi.org/10.3233/jad-2005-7203

38.

Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2(1):a006346. https://doi.org/10.1101/cshperspect.a006346CrossRef

39.

Takahashi RH, Nagao T, Gouras GK (2017) Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease. Pathol Int 67(4):185–193. https://doi.org/10.1111/pin.12520CrossRef

40.

Alonso R, Pisa D, Marina AI et al (2014) Fungal infection in patients with Alzheimer’s disease. J Alzheimers Dis 41(1):301–311. https://doi.org/10.3233/JAD-132681CrossRef

41.

Pisa D, Alonso R, Rábano A et al (2015) Different brain regions are infected with fungi in Alzheimer’s disease. Sci Rep 5:15015. https://doi.org/10.1038/srep15015CrossRef

42.

Jamieson GA, Maitland NJ, Wilcock GK et al (1992) Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol 167(4):365–368. https://doi.org/10.1002/path.1711670403CrossRef

43.

Letenneur L, Pérès K, Fleury H et al (2008) Seropositivity to herpes simplex virus antibodies and risk of Alzheimer’s disease: a population-based cohort study. PLoS ONE 3(11):e3637. https://doi.org/10.1371/journal.pone.0003637CrossRef

44.

L¨ovheim H, Gilthorpe J, Johansson A, et al (2015) Herpes simplex infection and the risk of Alzheimer’s disease: a nested case-control study. Alzheimers Dement 11:587–592. https://doi.org/10.1016/j.jalz.2014.07.157CrossRef

45.

Mancuso R, Baglio F, Cabinio M et al (2014) Titers of herpes simplex vírus type 1 antibodies positively correlate with grey matter volumes in Alzheimer’s disease. J Alzheimers Dis 38(4):741–745. https://doi.org/10.3233/JAD-130977CrossRef

46.

Cribbs DH, Azizeh BY, Cotman CW et al (2000) Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer’s A beta peptide. Biochemistry 39(20):5988–5994. https://doi.org/10.1021/bi000029fCrossRef

47.

Tallóczy Z, Virgin HW 4th, Levine B (2006) PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2(1):24–29. https://doi.org/10.4161/auto.2176CrossRef

48.

Wozniak MA, Frost AL, Itzhaki RF (2009) Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis 16(2):341–350. https://doi.org/10.3233/JAD-2009-0963CrossRef

49.

Valyi-Nagy T, Dermody TS (2005) Role of oxidative damage in the pathogenesis of viral infections of the nervous system. Histol Histopathol 20(3):957–967. https://doi.org/10.14670/HH-20.957CrossRef

50.

Santana S, Sastre I, Recuero M et al (2013) Oxidative stress enhances neurodegeneration markers induced by herpes simplex virus type 1 infection in human neuroblastoma cells. PLoS ONE 8(10):e75842. https://doi.org/10.1371/journal.pone.0075842CrossRef

51.

Aiello AE, Haan M, Blythe L et al (2006) The influence of latent viral infection on rate of cognitive decline over 4 years. J Am Geriatr Soc 54(7):1046–1054. https://doi.org/10.1111/j.1532-5415.2006.00796.xCrossRef

52.

Carbone I, Lazzarotto T, Ianni M et al (2014) Herpes virus in Alzheimer’s disease: relation to progression of the disease. Neurobiol Aging 35:122–129. https://doi.org/10.1016/j.neurobiolaging.2013.06.024CrossRef

53.

Barnes LL, Capuano AW, Aiello AE et al (2015) Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis 211(2):230–237. https://doi.org/10.1093/infdis/jiu437CrossRef

54.

Lin WR, Wozniak MA, Wilcock GK et al (2002) Cytomegalovirus is present in a very high proportion of brains from vascular dementia patients. Neurobiol Dis 9(1):82–87. https://doi.org/10.1006/nbdi.2001.0465CrossRef

55.

Almanzar G, Schwaiger S, Jenewein B et al (2005) Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 79(6):3675–3683. https://doi.org/10.1128/JVI.79.6.3675-3683.2005CrossRef

56.

Lurain NS, Hanson BA, Martinson J et al (2013) Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis 208(4):564–572. https://doi.org/10.1093/infdis/jit210CrossRef

57.

Yao K, Crawford JR, Komaroff AL et al (2010) Review part 2: Human herpesvirus-6 in central nervous system diseases. J Med Virol 82(10):1669–1678. https://doi.org/10.1002/jmv.21861CrossRef

58.

Lin WR, Wozniak MA, Cooper RJ et al (2002) Herpesviruses in brain and Alzheimer’s disease. J Pathol 197(3):395–402. https://doi.org/10.1002/path.1127CrossRef

59.

Romeo MA, Gilardini Montani MS, Gaeta A et al (1866) (2020) HHV-6A infection dysregulates autophagy/UPR interplay increasing beta amyloid production and tau phosphorylation in astrocytoma cells as well as in primary neurons, possible molecular mechanisms linking viral infection to Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis 3:165647. https://doi.org/10.1016/j.bbadis.2019.165647CrossRef

60.

Chiu WC, Tsan YT, Tsai SL et al (2014) Health data analysis in Taiwan (hDATa) Research Group. Hepatitis C viral infection and the risk of dementia. Eur J Neurol 21(8):1068-e59. https://doi.org/10.1111/ene.12317

61.

Senzolo M, Schiff S, D’Aloiso CM et al (2011) Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol 17(29):3369–3374. https://doi.org/10.3748/wjg.v17.i29.3369CrossRef

62.

Parkinson J (1817) An essay on the shaking palsy. Whittingham and Rowland for Sherwood, Needly and Jones, London

63.

Parkinsons’s Foundation. https://www.parkinson.org/Understanding-Parkinsons/Statistics. Accessed 2 Aug 2020

64.

Marras C, Beck JC, Bower JH et al (2018) Parkinson’s Foundation P4 Group. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis 4:21. https://doi.org/10.1038/s41531-018-0058-0CrossRef

65.

Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https://doi.org/10.1038/nrdp.2017.13CrossRef

66.

Grosch J, Winkler J, Kohl Z (2016) Early degeneration of both dopaminergic and serotonergic axons—a common mechanism in Parkinson’s disease. Front Cell Neurosci 10:293. https://doi.org/10.3389/fncel.2016.00293CrossRef

67.

Braak H, Tredici KD, Rüb U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211. https://doi.org/10.1016/s0197-4580(02)00065-9CrossRef

68.

Tavares A, Azeredo C (2003) Demência com corpos de Lewy: uma revisão para o psiquiatra. Rev Psiq Clín 30(1):29–34. https://doi.org/10.1590/S0101-60832003000100004CrossRef

69.

Mhyre TR, Boyd JT, Hamill RW et al (2012) Parkinson’s disease. Subcell Biochem 65:389–455. https://doi.org/10.1007/978-94-007-5416-4_16CrossRef

70.

Mohan M, Mellick GD (2017) Role of the VPS35 D620N mutation in Parkinson’s disease. Parkinsonism Related Disord 36:10–18. https://doi.org/10.1016/j.parkreldis.2016.12.001CrossRef

71.

Limphaibool N, Iwanowski P, Holstad MJV et al (2019) Infectious Etiologies of Parkinsonism: pathomechanisms and clinical implications. Front Neurol 10:652. https://doi.org/10.3389/fneur.2019.00652CrossRef

72.

Tanaka H, Park CH, Ninomiya A et al (2003) Neurotropism of the 1997 Hong Kong H5N1 influenza virus in mice. Vet Microbiol 95(1–2):1–13. https://doi.org/10.1016/s0378-1135(03)00132-9CrossRef

73.

Klopfleisch R, Werner O, Mundt E et al (2006) Neurotropism of highly pathogenic avian influenza virus A/chicken/Indonesia/2003 (H5N1) in experimentally infected pigeons (Columbialivia f. domestica). Vet Pathol 43(4):463–470. https://doi.org/10.1354/vp.43-4-463CrossRef

74.

Rigoni M, Shinya K, Toffan A et al (2007) Pneumo- and neurotropism of avian origin Italian highly pathogenic avian influenza H7N1 isolates in experimentally infected mice. Virology 364(1):28–35. https://doi.org/10.1016/j.virol.2007.02.031CrossRef

75.

Sadasivan S, Sharp B, Schultz-Cherry S et al (2017) Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis. NPJ Parkinsons Dis 3:18. https://doi.org/10.1038/s41531-017-0019-zCrossRef

76.

Bu XL, Wang X, Xiang Y et al (2015) The association between infectious burden and Parkinson’s disease: a case-control study. Parkinsonism Relat Disord 21(8):877–881. https://doi.org/10.1016/j.parkreldis.2015.05.015CrossRef

77.

Woulfe J, Hoogendoorn H, Tarnopolsky M et al (2000) Monoclonal antibodies against Epstein-Barr virus cross-react with α-synuclein in human brain. Neurology 55(9):1398–1440. https://doi.org/10.1212/wnl.55.9.1398CrossRef

78.

Caggiu E, Paulus K, Galleri G et al (2017) Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson’s disease. J Neuroimmunol 310:26–31. https://doi.org/10.1016/j.jneuroim.2017.06.004CrossRef

79.

Cury RG, Lopez WOC (2015) Bilateral striatal lesion due to herpesvirus-6 infection. J Neurol Sci 358(1–2):538–539. https://doi.org/10.1016/j.jns.2015.10.015CrossRef

80.

Goldeck D, Maetzler W, Berg D et al (2016) Altered dendritic cell subset distribution in patients with Parkinson’s disease: impact of cmv serostatus. J Neuroimmunol 290:60–65. https://doi.org/10.1016/j.jneuroim.2015.11.008CrossRef

81.

Koutsilieri E, Lutz MB, Scheller C (2013) Autoimmunity, dendritic cells and relevance for Parkinson’s disease. J Neural Transm (Vienna) 120(1):75–81. https://doi.org/10.1007/s00702-012-0842-7CrossRef

82.

Adinolfi LE, Nevola R, Lus G et al (2015) Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 21(8):2269–2280. https://doi.org/10.3748/wjg.v21.i8.2269CrossRef

83.

Wu WY, Kang KH, Chen SL et al (2015) Hepatitis C virus infection: a risk factor for Parkinson’s disease. J Viral Hepat 22(10):784–791. https://doi.org/10.1111/jvh.12392CrossRef

84.

Fletcher NF, Wilson GK, Murray J et al (2012) Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 142(3):634-643.e6. https://doi.org/10.1053/j.gastro.2011.11.028CrossRef

85.

Golabi P, Otgonsuren M, Sayiner M et al (2017) The prevalence of parkinson disease among patients with hepatitis C infection. Ann Hepatol 16(3):342–348. https://doi.org/10.5604/16652681.1235476CrossRef

86.

Berger JR, Nath A, Greenberg RN et al (2000) Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 4(4):921–926. https://doi.org/10.1212/WNL.54.4.921CrossRef

87.

Khanlou N, Moore DJ, Chana G et al (2009) Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol 15(2):131–138. https://doi.org/10.1080/13550280802578075CrossRef

88.

Puccini JM, Marker DF, Fitzgerald T et al (2015) Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. J Neurosci 35(13):5271–5283. https://doi.org/10.1523/JNEUROSCI.0650-14.2015CrossRef

89.

Josephson CB, Jetté N (2017) Psychiatric comorbidities in epilepsy. Int Rev Psychiatry 29(5):409–424. https://doi.org/10.1080/09540261.2017.1302412CrossRef

90.

Fisher RS, Acevedo C, Arzimanoglou A et al (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 4:475–482. https://doi.org/10.1111/epi.12550CrossRef

91.

Klein P, Tyrlikova I (2020) No prevention or cure of epilepsy as yet. Neuropharmacology 168:107762. https://doi.org/10.1016/j.neuropharm.2019.107762CrossRef

92.

Messori A, Polonara G, Carle F et al (2005) Predicting post-traumatic epilepsy with MRI: prospective longitudinal morphologic study in adults. Epilepsia 46(9):1472–1481. https://doi.org/10.1111/j.1528-1167.2005.34004.xCrossRef

93.

Gilad R, Lampl Y, Eilam A et al (2012) SPECT-DTPA as a tool for evaluating the blood-brain barrier in post-stroke seizures. J Neurol 259(10):2041–2044. https://doi.org/10.1007/s00415-012-6445-2CrossRef

94.

Klein P, Dingledine R, Aronica E et al (2018) Commonalities in epileptogenic processes from different acute brain insults: do they translate? Epilepsia 59(1):37–66. https://doi.org/10.1111/epi.13965CrossRef

95.

Del Brutto OH, Engel J Jr, Eliashiv DS et al (2016) Update on cysticercosis epileptogenesis: the role of the hippocampus. Curr Neurol Neurosci Rep 16(1):1. https://doi.org/10.1007/s11910-015-0601-xCrossRef

96.

Vezzani A, Fujinami RS, White HS et al (2016) Infections, inflammation and epilepsy. Acta Neuropathol 131(2):211–234. https://doi.org/10.1007/s00401-015-1481-5CrossRef

97.

Paudel YN, Shaikh MF, Shah S et al (2018) Role of inflammation in epilepsy and neurobehavioral comorbidities: implication for therapy. Eur J Pharmacol 837:145–155. https://doi.org/10.1016/j.ejphar.2018.08.020CrossRef

98.

Balosso S, Ravizza T, Aronica E et al (2013) The dual role of TNF-α and its receptors in seizures. Exp Neurol 247:267–271. https://doi.org/10.1016/j.expneurol.2013.05.010CrossRef

99.

Chikuma T, Yoshimoto T, Ohba M et al (2009) Interleukin-6 induces prostaglandin E(2) synthesis in mouse astrocytes. J Mol Neurosci 39(1–2):175–184. https://doi.org/10.1007/s12031-009-9187-6CrossRef

100.

Samland H, Huitron-Resendiz S, Masliah E et al (2003) Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res 73(2):176–187. https://doi.org/10.1002/jnr.10635CrossRef

101.

Singh A, Trevick S (2016) The epidemiology of global epilepsy. Neurol Clin 34(4):837–847. https://doi.org/10.1016/j.ncl.2016.06.015CrossRef

102.

Theodore WH (2014) Epilepsy and viral infections. Epilepsy Curr 14(1 Suppl):35–42. https://doi.org/10.5698/1535-7511-14.s2.35CrossRef

103.

Bartolini L, Libbey JE, Ravizza T et al (2019) Viral triggers and inflammatory mechanisms in pediatric epilepsy. Mol Neurobiol 56(3):1897–1907. https://doi.org/10.1007/s12035-018-1215-5CrossRef

104.

Bartolini L, Piras E, Sullivan K et al (2018) Detection of HHV-6 and EBV and cytokine levels in saliva from children with seizures: results of a multi-center cross-sectional study. Front Neurol 9:834. https://doi.org/10.3389/fneur.2018.00834CrossRef

105.

Niehusmann P, Mittelstaedt T, Bien CG et al (2010) Presence of human herpes virus 6 DNA exclusively in temporal lobe epilepsy brain tissue of patients with history of encephalitis. Epilepsia 51(12):2478–2483. https://doi.org/10.1111/j.1528-1167.2010.02741.xCrossRef

106.

Cuomo L, Trivedi P, Cardillo MR et al (2001) Human herpesvirus 6 infection in neoplastic and normal brain tissue. J Med Virol. 1:45–51 (PMID: 11130886)CrossRef

107.

Esposito L, Drexler JF, Braganza O et al (2015) Large-scale analysis of viral nucleic acid spectrum in temporal lobe epilepsy biopsies. Epilepsia 56(2):234–243. https://doi.org/10.1111/epi.12890CrossRef

108.

Fotheringham J, Donati D, Akhyani N et al (2007) Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med 5:e180. https://doi.org/10.1371/journal.pmed.0040180CrossRef

109.

Luppi M, Barozzi P, Maiorana A et al (1995) Human herpesvirus-6: a survey of presence and distribution of genomic sequences in normal brain and neuroglial tumors. J Med Virol 47(1):105–111. https://doi.org/10.1002/jmv.1890470119CrossRef

110.

Harberts E, Yao K, Wohler JE et al (2011) Human herpesvirus-6 entry into the central nervous system through the olfactory pathway. Proc Natl Acad Sci USA 108(33):13734–13739. https://doi.org/10.1073/pnas.1105143108CrossRef

111.

De Almeida SM, Crippa A, Cruz C et al (2015) Reactivation of herpes simplex virus-1 following epilepsy surgery. Epilepsy Behav Case Rep 4:76–78. https://doi.org/10.1016/j.ebcr.2014.08.007CrossRef

112.

Misra UK, Tan CT, Kalita J (2008) Viral encephalitis and epilepsy. Epilepsia 49(Suppl 6):13–18. https://doi.org/10.1111/j.1528-1167.2008.01751.xCrossRef

113.

Solomon T, Dung NM, Kneen R et al (2002) Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 125(Pt 5):1084–1093. https://doi.org/10.1093/brain/awf116CrossRef

114.

Jennische E, Eriksson CE, Lange S et al (2015) The anterior commissure is a pathway for contralateral spread of herpes simplex virus type 1 after olfactory tract infection. J Neurovirol 21(2):129–147. https://doi.org/10.1007/s13365-014-0312-0CrossRef

115.

Poulheim F, Esposito L, Elger CE et al (2017) Large-scale analysis of herpesviridae in epilepsy-patients with signs of autoimmune encephalitis. Seizure 53:100–102. https://doi.org/10.1016/j.seizure.2017.11.012CrossRef

116.

Suzuki Y, Toribe Y, Mogami Y et al (2008) Epilepsy in patients with congenital cytomegalovirus infection. Brain Dev 30(6):420–424. https://doi.org/10.1016/j.braindev.2007.12.004CrossRef

117.

Schleiss MR (2011) Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets 1(5):449–465. https://doi.org/10.2174/187152611797636721CrossRef

118.

Lei HY, Yang DQ, Li YX et al (2015) Association between human cytomegalovirus and onset of epilepsy. Int J Clin Exp Med 8(11):20556–20564 (PMID: 26884973)

119.

Rust RS (2014) Arbovirus Encephalitis. In: Aminoff MJ, Daroff RB (eds) Encyclopedia of the neurological sciences, 1st edn. Elsevier, Amsterdam, pp 260–270CrossRef

120.

Verma R, Varatharaj A (2011) Epilepsia partialis continua as a manifestation of dengue encephalitis. Epilepsy Behav 20(2):395–397. https://doi.org/10.1016/j.yebeh.2010.12.003CrossRef

121.

Guabiraba R, Ryffel B (2014) Dengue virus infection: current concepts in immune mechanisms and lessons from murine models. Immunology 141(2):143–156. https://doi.org/10.1111/imm.12188CrossRef

122.

Shresta S, Sharar KL, Prigozhin DM et al (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80(20):10208–10217. https://doi.org/10.1128/JVI.00062-06CrossRef

123.

Johnson AJ, Roehrig JT (1999) New mouse model for dengue virus vaccine testing. J Virol 73(1):783–786. https://doi.org/10.1128/JVI.73.1.783-786.1999CrossRef

124.

Kellinghaus C, Engbring C, Kovac S et al (2008) Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure 17(1):27–33. https://doi.org/10.1016/j.seizure.2007.05.017CrossRef

125.

Ssentongo P (2019) Prevalence and incidence of new-onset seizures and epilepsy in patients with human immunodeficiency virus (HIV): systematic review and meta-analysis. Epilepsy Behav 93:49–55. https://doi.org/10.1016/j.yebeh.2019.01.033CrossRef

126.

Devinsky O, Vezzani A, O’Brien TJ et al (2018) Epilepsy. Nat Rev Dis Primers 4:18024. https://doi.org/10.1038/nrdp.2018.24CrossRef

127.

Garg RK (1999) HIV infection and seizures. Postgrad Med J 75(885):387–390. https://doi.org/10.1136/pgmj.75.885.387CrossRef

128.

Vezzani A (2014) Epilepsy and inflammation in the brain: overview and pathophysiology. Epilepsy Curr 14(1 Suppl):3–7. https://doi.org/10.5698/1535-7511-14.s2.3CrossRef

129.

Brownlee WJ, Hardy TA, Fazekas F et al (2017) Diagnosis of multiple sclerosis: progress and challenges. Lancet 389(10076):1336–1346. https://doi.org/10.1016/S0140-6736(16)30959-XCrossRef

130.

Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286. https://doi.org/10.1212/WNL.0000000000000560CrossRef

131.

Ochi H (2014) Cognitive impairment in multiple sclerosis. Brain Nerve 66(10):1201–1209. https://doi.org/10.11477/mf.1416200011CrossRef

132.

Tomassini V, Johansen-Berg H, Leonardi L et al (2011) Preservation of motor skill learning in patients with multiple sclerosis. Mult Scler 17(1):103–115. https://doi.org/10.1177/1352458510381257CrossRef

133.

Maitin IB, Cruz E (2018) Special considerations and assessment in patients with multiple sclerosis. Phys Med Rehabil Clin N Am 29(3):473–481. https://doi.org/10.1016/j.pmr.2018.03.003CrossRef

134.

Eskandarieh S, Heydarpour P, Minagar A et al (2016) Multiple Sclerosis epidemiology in East Asia, South East Asia and South Asia: a systematic review. Neuroepidemiology 46(3):209–221. https://doi.org/10.1159/000444019CrossRef

135.

Gilmour H, Ramage-Morin PL, Wong SL (2018) Multiple sclerosis: prevalence and impact. Health Rep 29(1):3–8 (PMID: 29341025)

136.

Afshar B, Khalifehzadeh-Esfahani Z, Seyfizadeh N et al (2019) The role of immune regulatory molecules in multiple sclerosis. J Neuroimmunol 337:577061. https://doi.org/10.1016/j.jneuroim.2019.577061CrossRef

137.

Sadovnick AD, Risch NJ, Ebers GC (1998) Canadian collaborative project on genetic susceptibility to MS, phase 2: rationale and method. Canadian Collaborative Study Group. Can J Neurol Sci 25(3):216–221. https://doi.org/10.1017/s0317167100034041CrossRef

138.

Sadovnick D (2019) The place of environmental factors in multiple sclerosis: genes, environment and the interactions thereof in the etiology of multiple sclerosis. Rev Neurol 175(10):593–596. https://doi.org/10.1016/j.neurol.2019.08.003CrossRef

139.

Virtanen JO, Jacobson S (2012) Viruses and multiple sclerosis. CNS Neurol Disord Drug Targets 11(5):528–544. https://doi.org/10.2174/187152712801661220CrossRef

140.

Kb F, Jhd M, Haire M et al (1979) Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet 314:715–717. https://doi.org/10.1016/S0140-6736(79)90643-3CrossRef

141.

Ahmed SI, Aziz K, Gul A et al (2019) Risk of multiple sclerosis in Epstein–Barr virus infection. Cureus 11(9):e5699. https://doi.org/10.7759/cureus.5699CrossRef

142.

De Jager PL, Simon KC, Munger KL et al (2008) Integrating risk factors: HLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosis. Neurology 70(13 Pt 2):1113–1118. https://doi.org/10.1212/01.wnl.0000294325.63006.f8CrossRef

143.

Guan Y, Jakimovski D, Ramanathan M et al (2019) The role of Epstein–Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging. Neural Regen Res 14(3):373–386. https://doi.org/10.4103/1673-5374.245462CrossRef

144.

Küry P, Nath A, Créange A et al (2018) Human endogenous retroviruses in neurological diseases. Trends Mol Med 24(4):379–394. https://doi.org/10.1016/j.molmed.2018.02.007CrossRef

145.

Grandi N, Tramontano E (2018) Human endogenous retroviruses are ancient acquired elements still shaping innate immune responses. Front Immunol 9:2039. https://doi.org/10.3389/fimmu.2018.02039CrossRef

146.

Khan G, Hassani A (2019) Epstein–Barr virus in multiple sclerosis. In: Baloyannis SJ (ed) Multiple sclerosis. Intechopen. https://doi.org/10.5772/intechopen.85222. https://www.intechopen.com/books/multiple-sclerosis/epstein-barr-virus-in-multiple-sclerosis

147.

Linington C, Kaushansky N, Chapple K, Ben-Nun A (2014) Myelin oligodendrocyte glycoprotein (MOG): an archetypal target for demyelinating autoantibodies in the central nervous system. In: Autoantibodies, 3rd edn. Elsvier, pp 617–627. https://doi.org/10.1016/B978-0-444-56378-1.00073-3

148.

Jagessar SA, Holtman IR, Hofman S et al (2016) Lymphocryptovirus infection of nonhuman primate B cells converts destructive into productive processing of the pathogenic CD8 T cell epitope in myelin oligodendrocyte glycoprotein. J Immunol 197(4):1074–1088. https://doi.org/10.4049/jimmunol.1600124CrossRef

149.

Ruprecht K, Wildemann B, Jarius S (2018) Low intrathecal antibody production despite high seroprevalence of Epstein–Barr virus in multiple sclerosis: a review of the literature. J Neurol 265(2):239–252. https://doi.org/10.1007/s00415-017-8656-zCrossRef

150.

Jarius S, Eichhorn P, Franciotta D et al (2017) The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol 264(3):453–466. https://doi.org/10.1007/s00415-016-8360-4CrossRef

151.

Akhyani N, Berti R, Brennan MB et al (2000) Tissue distribution and variant characterization of human herpesvirus (HHV)-6: increased prevalence of HHV-6A in patients with multiple sclerosis. J Infect Dis 182(5):1321–1325. https://doi.org/10.1086/315893CrossRef

152.

Leibovitch EC, Brunetto GS, Caruso B et al (2014) Coinfection of human herpesviruses 6A (HHV-6A) and HHV-6B as demonstrated by novel digital droplet PCR assay. PLoS ONE 9(3):e92328. https://doi.org/10.1371/journal.pone.0092328CrossRef

153.

Reynaud JM, Jégou JF, Welsch JC et al (2014) Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9. J Virol 88(10):5421–5436. https://doi.org/10.1128/JVI.03763-13CrossRef

154.

Engdahl E, Gustafsson R, Huang J et al (2019) Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis. Front Immunol 10:2715. https://doi.org/10.3389/fimmu.2019.02715CrossRef

155.

Ahlqvist J, Fotheringham J, Akhyani N et al (2005) Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J Neurovirol 11(4):384–394. https://doi.org/10.1080/13550280591002379CrossRef

156.

Campbell A, Hogestyn JM, Folts CJ et al (2017) Expression of the human herpesvirus 6A latency-associated transcript U94A disrupts human oligodendrocyte progenitor migration. Sci Rep 7(1):3978. https://doi.org/10.1038/s41598-017-04432-yCrossRef

157.

McGrogan A, Madle GC, Seaman HE et al (2008) The epidemiology of Guillain–Barré syndrome worldwide A systematic literature review. Neuroepidemiology 32(2):150–163. https://doi.org/10.1159/000184748CrossRef

158.

Ansar V, Valadi N (2015) Guillain–Barré syndrome. Prim Care 42(2):189–193. https://doi.org/10.1016/j.pop.2015.01.001CrossRef

159.

Malek E, Salameh J (2019) Guillain–Barre syndrome. Semin Neurol 39(5):589–595. https://doi.org/10.1055/s-0039-1693005CrossRef

160.

Leung J, Sejvar JJ, Soares J et al (2019) Guillain–Barré syndrome and antecedent cytomegalovirus infection, USA 2009–2015. Neurol Sci 41(4):885–891. https://doi.org/10.1007/s10072-019-04156-zCrossRef

161.

Tavares AC, Alves CBL, Silva MA et al (2000) Síndrome de Guillain–Barré: revisão de literatura. Cad Bras Med 13(1):2. ISSN 2412-2688

162.

Rodríguez Y, Rojas M, Pacheco Y et al (2018) Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol 15(6):547–562. https://doi.org/10.1038/cmi.2017.142CrossRef

163.

Kaida K (2019) Guillain–Barré syndrome. Adv Exp Med Biol 1190:323–331. https://doi.org/10.1007/978-981-32-9636-7_20CrossRef

164.

Blum S, McCombe PA (2014) Genetics of Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst 19(2):88–103. https://doi.org/10.1111/jns5.12074CrossRef

165.

Dilena R, Strazzer S, Esposito S et al (2016) Locked-in-like fulminant infantile Guillain–Barré syndrome associated with herpes simplex virus 1 infection. Muscle Nerve 53(1):140–143. https://doi.org/10.1002/mus.24908CrossRef

166.

Yuki N, Susuki K, Odaka M et al (2001) Overlapping Guillain–Barré syndrome and Bickerstaff’s brainstem encephalitis associated with anti-GQ1b IgG antibody after herpes simplex virus infection. Acta Neurol Scand 104(1):57–60. https://doi.org/10.1034/j.1600-0404.2001.00288.xCrossRef

167.

Ang CW, Jacobs BC, Brandenburg AH et al (2000) Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain–Barré syndrome. Neurology 54(7):1453–1458. https://doi.org/10.1212/wnl.54.7.1453CrossRef

168.

Miyaji K, Furukawa JI, Suzuki Y et al (2016) Altered gene expression of glycosyltransferases and sialyltransferases and total amount of glycosphingolipids following herpes simplex virus infection. Carbohydr Res 434:37–43. https://doi.org/10.1016/j.carres.2016.08.004CrossRef

169.

Klemola E, Weckman N, Haltia K et al (1967) The Guillain–Barré syndrome associated with acquired cytomegalovirus infection. Acta Med Scand 181(5):603–607. https://doi.org/10.1111/j.0954-6820.1967.tb07283.xCrossRef

170.

Irie S, Saito T, Nakamura K et al (1996) Association of anti-GM2 antibodies in Guillain–Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 68(1–2):19–26. https://doi.org/10.1016/0165-5728(96)00059-8CrossRef

171.

Sawai S, Satoh M, Mori M et al (2014) Moesin is a possible target molecule for cytomegalovirus-related Guillain–Barré syndrome. Neurology 83(2):113–117. https://doi.org/10.1212/WNL.0000000000000566CrossRef

172.

Merelli E, Sola P, Faglioni P et al (1992) Newest human herpesvirus (HHV-6) in the Guillain–Barré syndrome and other neurological diseases. Acta Neurol Scand 85(5):334–336. https://doi.org/10.1111/j.1600-0404.1992.tb04054.xCrossRef

173.

Masajtis-Zagajewska A, Muras K, Mochecka-Thoelke A et al (2012) Guillain–Barré syndrome in the course of EBV infection after kidney transplantation—a case report. Ann Transplant 17(3):133–137. https://doi.org/10.12659/aot.883468CrossRef

174.

Grose C, Feorino P (1972) Epstein–Barr virus and Guillain–Barré syndrome. Lancet 300(7790):1285–1287. https://doi.org/10.1016/S0140-6736(72)92654-2CrossRef

175.

Kennedy M, Apostolova M (2013) A rare case of infectious mononucleosis complicated by Guillain–Barre syndrome. Neurol Int 5(2):20–22. https://doi.org/10.4081/ni.2013.e7CrossRef

176.

Yamana M, Kuwahara M, Fukumoto Y et al (2019) Guillain–Barré syndrome and related diseases after influenza virus infection. Neurol Neuroimmunol Neuroinflamm 6(4):e575. https://doi.org/10.1212/NXI.0000000000000575CrossRef

177.

De Klippel N, Hautekeete ML, De Keyser J et al (1993) Guillain–Barré syndrome as the presenting manifestation of hepatitis C infection. Neurology 43(10):2143. https://doi.org/10.1212/wnl.43.10.2143CrossRef

178.

Molokwu O, Young BM, Singh M et al (2019) Reactivation of chronic hepatitis C as a potential trigger for Guillain–Barré syndrome. Cureus 11(7):e5244. https://doi.org/10.7759/cureus.5244CrossRef

179.

Lacaille F, Zylberberg H, Hagège H et al (1998) Hepatitis C associated with Guillain–Barré syndrome. Liver 18(1):49–51. https://doi.org/10.1111/j.1600-0676.1998.tb00126.xCrossRef

180.

Chlilek A, Roger C, Muller L et al (2019) Severe Guillain–Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report. BMC Infect Dis 19(1):636. https://doi.org/10.1186/s12879-019-4278-7CrossRef

181.

Mariotto S, Ferrari S, Monaco S (2014) HCV-related central and peripheral nervous system demyelinating disorders. Inflamm Allergy Drug Targets 13(5):299–304. https://doi.org/10.2174/1871528113666140908113841CrossRef

182.

Shah I (2007) Dengue presenting as Guillain–Barre syndrome. Dengue Bull. 31:166–8. https://apps.who.int/iris/bitstream/handle/10665/170357/db2007v31p166.pdf?sequence=1&isAllowed=y. Accessed 4 Aug 2020

183.

Oishi K, Saito M, Mapua CA et al (2007) Dengue illness: clinical features and pathogenesis. J Infect Chemother 13(3):125–133. https://doi.org/10.1007/s10156-007-0516-9CrossRef

184.

Latorre FG, Magalhães GO, Costa ISL et al (2019) Síndrome de Guillain–Barré como complicação da infecção pelo vírus da dengue. Braz J Surg Clin Res 28(1): 25–29. ISSN online: 2317-4404

185.

Wakerley BR, Yuki N (2013) Infectious and noninfectious triggers in Guillain–Barré syndrome. Expert Rev Clin Immunol 9(7):627–639. https://doi.org/10.1586/1744666X.2013.811119CrossRef

186.

Henning F, Bouic P (2014) Increased frequency of Guillain–Barré syndrome in HIV infection: a prospective cohort study. J AIDS Clin Res 5(8):1–5. https://doi.org/10.4172/2155-6113.1000332CrossRef

187.

Fantauzzi A, Digiulio MA, Cavallari EN et al (2014) Guillain Barre syndrome in an HIV-1-infected patient after the beginning of combined antiretroviral therapy: an immune reconstitution inflammatory syndrome? New Microbiol 37(1):103–107 (PMID: 24531178)

188.

Spindler KR, Hsu TH (2012) Viral disruption of the blood-brain barrier. Trends Microbiol 20(6):282–290. https://doi.org/10.1016/j.tim.2012.03.009CrossRef

189.

Keswani SC, Polley M, Pardo CA et al (2003) Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 54(3):287–296. https://doi.org/10.1002/ana.10645CrossRef

190.

World Health Organization (WHO) (2020) Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it Accessed 2 Aug 2020

191.

Callaway E, Cyranoski D, Mallapaty S et al (2020) The coronavirus pandemic in five powerful charts. Nature 579(7800):482–483. https://doi.org/10.1038/d41586-020-00758-2CrossRef

192.

Matías-Guiu J, Gomez-Pinedo U, Montero-Escribano P et al (2020) Es esperable que haya cuadros neurológicos por la pandemia de SARS2-CoV? Neurología 35(3):170–175. https://doi.org/10.1016/j.nrl.2020.03.001CrossRef

193.

Kim JE, Heo JH, Kim HO et al (2017) Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol 13(3):227–233. https://doi.org/10.3988/jcn.2017.13.3.227CrossRef

194.

Tsai LK, Hsieh ST, Chao CC et al (2004) Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 61(11):1669–1673. https://doi.org/10.1001/archneur.61.11.1669CrossRef

195.

Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):1–9. https://doi.org/10.1001/jamaneurol.2020.1127CrossRef

196.

Helms J, Kremer S, Merdji H et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382(23):2268–2270. https://doi.org/10.1056/NEJMc2008597CrossRef

197.

Ogier M, Andéol G, Sagui E et al (2020) How to detect and track chronic neurologic sequelae of covid-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. Brain Behav Immun Health 5:100081. https://doi.org/10.1016/j.bbih.2020.100081CrossRef

198.

Baig AM, Khaleeq A, Ali U, Syeda H (2020) Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11(7):995–998. https://doi.org/10.1021/acschemneuro.0c00122CrossRef

199.

Xiang P, Xu XM, Gao LL et al (2019) First case of 2019 novel coronavirus disease with encephalitis. ChinaXiv T 202003:00015

200.

Moriguchi T, Harii N, Goto J et al (2020) A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int J Infect Dis 94:55–58. https://doi.org/10.1016/j.ijid.2020.03.062CrossRef

201.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRef

202.

Sejvar JJ, Baughman AL, Wise M et al (2011) Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36(2):123–133. https://doi.org/10.1159/000324710CrossRef

203.

Sedaghat Z, Karimi N (2020) Guillain–Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci S0967–5868(20):30882–30891. https://doi.org/10.1016/j.jocn.2020.04.062CrossRef

204.

Zhao H, Shen D, Zhou H et al (2020) Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19(5):383–384. https://doi.org/10.1016/S1474-4422(20)30109-5CrossRef

205.

Vollono C, Rollo E, Romozzi M et al (2020) Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure 78:109–112. https://doi.org/10.1016/j.seizure.2020.04.009CrossRef

206.

Kuroda N (2020) Epilepsy and COVID-19: associations and important considerations. Epilepsy Behav 108:107122. https://doi.org/10.1016/j.yebeh.2020.107122CrossRef

207.

Arbour N, Day R, Newcombe J et al (2000) Neuroinvasion by human respiratory coronaviruses. J Virol 4(19):8913–8921. https://doi.org/10.1128/jvi.74.19.8913-8921.2000CrossRef

208.

Wilson MP, Jack AS (2020) Coronavirus disease 2019 (COVID-19) in neurology and neurosurgery: a scoping review of the early literature. Clin Neurol Neurosurg 193:105866. https://doi.org/10.1016/j.clineuro.2020.105866CrossRef

209.

Troyer EA, Kohn JN, Hong S (2020) Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun 87:34–39. https://doi.org/10.1016/j.bbi.2020.04.027CrossRef

210.

Frank-Cannon TC, Alto LT, McAlpine FE et al (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47. https://doi.org/10.1186/1750-1326-4-47CrossRef

211.

Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P et al (2020) Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia 35(4):245–251. https://doi.org/10.1016/j.nrl.2020.04.002CrossRef

212.

Poyiadji N, Shahin G, Noujaim D et al (2020) COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology 296(2):E119–E120. https://doi.org/10.1148/radiol.2020201187CrossRef

213.

Ziegler CGK, Allon SJ, Nyquist SK et al (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(5):1016-1035.e19. https://doi.org/10.1016/j.cell.2020.04.035CrossRef

Titel: Viral infections and their relationship to neurological disorders
verfasst von: Jéssica Wouk
Daniele Zendrini Rechenchoski
Bianca Cerqueira Dias Rodrigues
Elisa Vicente Ribelato
Ligia Carla Faccin-Galhardi
Publikationsdatum: 27.01.2021
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 3/2021
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-021-04959-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Viral infections and their relationship to neurological disorders

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Prevalence and genetic variability of grapevine virus A in Turkish autochthonous grapevine varieties

Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions

Genetic diversity and recombination between turnip yellows virus strains in Australia

Complete genome sequence of Sikte (Sitke) waterborne virus, a member of the genus Tombusvirus

Genomic characterization of a nebovirus strain with a novel RdRp genotype in yaks

C1QBP inhibits proliferation of porcine circovirus type 2 by restricting nuclear import of the capsid protein

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin